Cumberland Pharmaceuticals (CPIX) Total Non-Current Liabilities (2010 - 2026)

Cumberland Pharmaceuticals has reported Total Non-Current Liabilities for 17 years, with the latest figure at $44.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 23.84% year-over-year to $44.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.1 million (up 23.84% YoY) and the FY2025 annual result came in at $46.5 million, down 0.6% from the prior year.
• Total Non-Current Liabilities retreated to $44.1 million in Q1 2026 per CPIX's latest filing, from $46.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $49.4 million in Q4 2022 and troughed at $33.9 million in Q2 2025.
• A 5-year average of $43.8 million and a median of $45.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 43.64% in 2022, then dropped 26.16% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $49.4 million in 2022, then slipped by 6.69% to $46.1 million in 2023, then rose by 1.47% to $46.7 million in 2024, then retreated by 0.6% to $46.5 million in 2025, then fell by 5.13% to $44.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $44.1 million, $46.5 million, and $34.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.